On January 5, 2026, Catherine A. Sohn, a director at Altimmune, Inc. (NASDAQ:ALT), made a significant investment in the company by purchasing 500 shares of the company's common stock at approximately $4.24 per share. This purchase increased her total ownership to 1,500 shares. Altimmune is a leading biopharmaceutical company that focuses on developing therapies for serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH).
Altimmune recently received a significant boost as the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for its drug, pemvidutide. This designation is intended to expedite the development and review process for drugs that show potential for substantial improvement over existing therapies for serious conditions. The FDA's decision underscores the promising clinical profile of pemvidutide.
The company has reported robust 48-week Phase IIb data for pemvidutide in treating MASH, supporting its progression to Phase III trials. The data showed durable, dose-dependent improvements in non-invasive fibrosis markers and consistent safety. Notably, patients experienced a weight loss of 7.5% at a 1.8 mg dose, which is promising for future trials.
Altimmune is optimistic about regulatory alignment for a Phase III trial, which aims for accelerated approval. This trial will focus on biopsy-based endpoints and plans to test a 2.4 mg dose. The company's stock, currently priced at $4.09, has seen a significant increase of 16.52%, with a change of $0.58, reflecting investor confidence in its potential.
The stock has fluctuated between a low of $3.97 and a high of $4.53 today. Over the past year, ALT has reached a high of $7.83 and a low of $2.90. With a market capitalization of approximately $361 million and a trading volume of 26.77 million shares, Altimmune is positioned for growth as it advances its promising drug pipeline.
